APPLICATION
ANDA205629
TYPE
ANDA
ORIGINAL APPROVAL
2016-07-07
LATEST ACTION
2026-06-18
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription
Products
HYDROMORPHONE HYDROCHLORIDEPrescription
HYDROMORPHONE HYDROCHLORIDE 12MG · TABLET, EXTENDED RELEASE · ORAL
HYDROMORPHONE HYDROCHLORIDEPrescription
HYDROMORPHONE HYDROCHLORIDE 24MG · TABLET, EXTENDED RELEASE · ORAL
HYDROMORPHONE HYDROCHLORIDEPrescription
HYDROMORPHONE HYDROCHLORIDE 16MG · TABLET, EXTENDED RELEASE · ORAL
HYDROMORPHONE HYDROCHLORIDEPrescription
HYDROMORPHONE HYDROCHLORIDE 8MG · TABLET, EXTENDED RELEASE · ORAL
HYDROMORPHONE HYDROCHLORIDEPrescription
HYDROMORPHONE HYDROCHLORIDE 32MG · TABLET, EXTENDED RELEASE · ORAL
Approval history
2026-06-18REMS · Supplement 23AP
2025-12-22Labeling · Supplement 22 · standardAP
2024-10-31REMS · Supplement 21AP
2024-10-30Manufacturing (CMC) · Supplement 20 · unknownAP
2024-03-12Labeling · Supplement 19 · standardAP
2023-12-15Labeling · Supplement 18 · standardAP
2023-12-15Labeling · Supplement 16 · standardAP
2021-03-04Labeling · Supplement 13 · standardAP
2021-03-03Labeling · Supplement 7 · standardAP
2021-03-03Labeling · Supplement 11 · standardAP
2018-09-18REMS · Supplement 6AP
2017-05-26REMS · Supplement 3AP
2016-09-30REMS · Supplement 1AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.